|Articles|July 5, 2018
Why One Korean Biotech Picked New Jersey for U.S. Headquarters
Author(s)Michelle Maskaly
New Jersey is still a top pick for companies when it comes to pharma.
Advertisement
Ki-Young Sohn, chairman and CEO of Enzychem Lifesciences, explains why the company selected New Jersey as the location for their U.S. offices.
He spoke to Pharm Exec during a company event in New York City.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?
2
Staying Ahead of Viral Evolution: Q&A with Robert Allen, Ph.D
3
Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory
4
Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement
5